Is Clinical Complete Response As Accurate As Pathological Complete Response in Patients with Mid-low Locally Advanced Rectal Cancer?

Overview

Journal Ann Coloproctol

Date 2025 Mar 5

PMID 40044112

Authors

Niyaz Shadmanov

Vusal Aliyev

Guglielmo Niccolo Piozzi

Baris Bakir

Suha Goksel

Oktar Asoglu

Affiliations

Soon will be listed here.

Abstract

Purpose: The standard treatment for locally advanced rectal cancer involves neoadjuvant chemoradiation followed by total mesorectal excision surgery. A subset of patients achieves pathologic complete response (pCR), representing the optimal treatment outcome. This study compares the long-term oncological outcomes of patients who achieved pCR with those who attained clinical complete response (cCR) after total neoadjuvant therapy, managed using a watch-and-wait approach.

Methods: This study retrospectively evaluated patients with mid-low locally advanced rectal cancer who underwent neoadjuvant treatment from January 1, 2005, to May 1, 2023. The pCR and cCR groups were compared based on demographic, clinical, histopathological, and long-term survival outcomes.

Results: The median follow-up times were 54 months (range, 7-83 months) for the cCR group (n=73), 96 months (range, 7-215 months) for the pCR group (n=63), and 72 months (range, 4-212 months) for the pathological incomplete clinical response (pICR) group (n=627). In the cCR group, 15 patients (20.5%) experienced local regrowth, and 5 (6.8%) developed distant metastasis (DM). The pCR group had no cases of local recurrence, but 3 patients (4.8%) developed DM. Among the pICR patients, 58 (9.2%) experienced local recurrence, and 92 (14.6%) had DM. Five-year disease-free survival rates were 90.0% for cCR, 92.0% for pCR, and 69.5% for pICR (P=0.022). Five-year overall survival rates were 93.1% for cCR, 92.0% for pCR, and 78.1% for pICR. There were no significant differences in outcomes between the cCR and pCR groups (P=0.810); however, the pICR group exhibited poorer outcomes (P=0.002).

Conclusions: This study shows no significant long-term oncological differences between patients who exhibited cCR and those who experienced pCR.

References

Asoglu O, Goksoy B, Aliyev V, Mustafayev T, Atalar B, Bakir B . Watch and Wait Strategy for Rectal Cancer: How Long Should We Wait for a Clinical Complete Response?. Surg Technol Int. 2022; 40:130-139. DOI: 10.52198/22.STI.40.CR1507. View

Habr-Gama A, Gama-Rodrigues J, Sao Juliao G, Proscurshim I, Sabbagh C, Lynn P . Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014; 88(4):822-8. DOI: 10.1016/j.ijrobp.2013.12.012. View

Geubels B, Meyer V, van Westreenen H, Beets G, Grotenhuis B, The Dutch Watch And Wait Consortium . Role of Local Excision for Suspected Regrowth in a Watch and Wait Strategy for Rectal Cancer. Cancers (Basel). 2022; 14(13). PMC: 9265129. DOI: 10.3390/cancers14133071. View

Dinnewitzer A, Jager T, Nawara C, Buchner S, Wolfgang H, Ofner D . Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer. Dis Colon Rectum. 2013; 56(10):1134-42. DOI: 10.1097/DCR.0b013e31829ef472. View

de Caluwe L, van Nieuwenhove Y, Ceelen W . Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2013; (2):CD006041. PMC: 10116849. DOI: 10.1002/14651858.CD006041.pub3. View

Garcia-Aguilar J, Chow O, Smith D, Marcet J, Cataldo P, Varma M . Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015; 16(8):957-66. PMC: 4670237. DOI: 10.1016/S1470-2045(15)00004-2. View

Guren M, Eriksen M, Wiig J, Carlsen E, Nesbakken A, Sigurdsson H . Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur J Surg Oncol. 2005; 31(7):735-42. DOI: 10.1016/j.ejso.2005.05.004. View

Nasir I, Fernandez L, Vieira P, Pares O, Santiago I, Castillo-Martin M . Salvage surgery for local regrowths in Watch & Wait - Are we harming our patients by deferring the surgery?. Eur J Surg Oncol. 2019; 45(9):1559-1566. DOI: 10.1016/j.ejso.2019.04.006. View

Quirke P, Risio M, Lambert R, von Karsa L, Vieth M . Quality assurance in pathology in colorectal cancer screening and diagnosis—European recommendations. Virchows Arch. 2010; 458(1):1-19. PMC: 3016207. DOI: 10.1007/s00428-010-0977-6. View

10.

Enriquez-Navascues J, Borda N, Lizerazu A, Placer C, Elosegui J, Ciria J . Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World J Gastroenterol. 2011; 17(13):1674-84. PMC: 3072630. DOI: 10.3748/wjg.v17.i13.1674. View

11.

Habr-Gama A, Perez R, Wynn G, Marks J, Kessler H, Gama-Rodrigues J . Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010; 53(12):1692-8. DOI: 10.1007/DCR.0b013e3181f42b89. View

12.

Heald R, Ryall R . Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986; 1(8496):1479-82. DOI: 10.1016/s0140-6736(86)91510-2. View

13.

Wanebo H, Antoniuk P, Koness R, Levy A, Vezeridis M, COHEN S . Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum. 1999; 42(11):1438-48. DOI: 10.1007/BF02235044. View

14.

Garcia-Aguilar J, Patil S, Gollub M, Kim J, Yuval J, Thompson H . Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022; 40(23):2546-2556. PMC: 9362876. DOI: 10.1200/JCO.22.00032. View

15.

Aliyev V, Arslan N, Goksoy B, Guven K, Goksel S, Asoglu O . Is robotic da Vinci Xi® superior to the da Vinci Si® for sphincter-preserving total mesorectal excision? Outcomes in 150 mid-low rectal cancer patients. J Robot Surg. 2022; 16(6):1339-1346. DOI: 10.1007/s11701-021-01356-8. View

16.

Asoglu O, Bulut A, Aliyev V, Piozzi G, Guven K, Bakir B . Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series. World J Surg Oncol. 2022; 20(1):358. PMC: 9646475. DOI: 10.1186/s12957-022-02816-7. View

17.

Asoglu O, Tokmak H, Bakir B, Demir G, Ozyar E, Atalar B . The impact of total neo-adjuvant treatment on nonoperative management in patients with locally advanced rectal cancer: The evaluation of 66 cases. Eur J Surg Oncol. 2020; 46(3):402-409. DOI: 10.1016/j.ejso.2019.07.012. View

18.

Rettig R, Beard B, Ryoo J, Kulkarni S, Gulati M, Tam M . Total Neoadjuvant Therapy Significantly Increases Complete Clinical Response. Dis Colon Rectum. 2022; 66(3):374-382. DOI: 10.1097/DCR.0000000000002290. View

19.

Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J . International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021; 18(12):805-816. DOI: 10.1038/s41571-021-00538-5. View

20.

Wibe A, Moller B, Norstein J, Carlsen E, Wiig J, Heald R . A national strategic change in treatment policy for rectal cancer--implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum. 2002; 45(7):857-66. DOI: 10.1007/s10350-004-6317-7. View